# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k170416   
B. Purpose for Submission: New Device   
C. Measurand: EDDP (2-ethylidene-1,5-dimethyl-3,3- diphenylpyrrolidine)   
D. Type of Test: Qualitative and Semi-Quantitative Assay   
E. Applicant: Lin-Zhi International, Inc.   
F. Proprietary and Established Names: LZI Methadone Metabolite (EDDP) Enzyme Immunoassay LZI Methadone Metabolite (EDDP) (100 and 300) Calibrators

G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DJR</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>862.3620</td><td rowspan=1 colspan=1>91-Toxicology</td></tr><tr><td rowspan=1 colspan=1>DLJ</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>862.3200</td><td rowspan=1 colspan=1>91-Toxicology</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indication for use below.

The LZI Methadone Metabolite (EDDP) Enzyme Immunoassay is an in vitro diagnostic test intended for the qualitative and semi-quantitative determination of Methadone Metabolite in human urine. The cutoff for both the qualitative and semi-quantitative modes of the assay are $1 0 0 ~ \mathrm { { n g / m L } }$ and $3 0 0 ~ \mathrm { { n g / m L } }$ for Methadone Metabolite. The assay is designed for prescription use on automated clinical chemistry analyzers.

The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Gas or liquid chromatography/mass spectrometry (GC/MS or LC/MS)or (2) permitting laboratories to establish quality control procedures.

The assay provides only a preliminary analytical result. A more specific alternative analytical chemistry method must be used in order to obtain a confirmed analytical result. Gas or liquid chromatography/mass spectrometry (GC/MS or LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

The LZI Methadone Metabolite (EDDP) (100 and 300) Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the LZI Methadone Metabolite (EDDP) Enzyme Immunoassay at the cutoff values of $1 0 0 ~ \mathrm { { n g / m L } }$ and 300 $\mathrm { { n g / m L } }$ .

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Performance data was obtained using the Beckman Coulter AU480 Analyzer.

# I. Device Description:

The LZI Methadone Metabolite (EDDP) Enzyme Immunoassay is comprised of two reagents, R1 and R2, which are provided as ready to use liquids. The R1 solution contains mouse monoclonal anti-methadone metabolite antibody, glucose-6-phosphate (G6P), nicotinamide adenine dinucleotide (NAD), stabilizers, and sodium azide $( 0 . 0 9 \% )$ as a preservative. The R2 solution contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with methadone metabolite in buffer with sodium azide $( 0 . 0 9 \% )$ as a preservative.

The LZI Methadone Metabolite (EDDP) 100 Calibrators contain 0, 50, 100, 250, and 500 $\mathrm { n g / m L }$ of methadone metabolite (EDDP) in human urine with sodium azide as a preservative. These five calibrators are sold as liquid, ready to use individual bottles.

The LZI Methadone Metabolite (EDDP) 300 Calibrators contain 0, 150, 300, 650, and 1000 $\mathrm { n g / m L }$ of methadone metabolite (EDDP) in human urine with sodium azide as a preservative. These calibrators are sold as liquid, ready to use individual bottles.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Lin-Zhi International, Inc Methadone Metabolite Enzyme Immunoassay

2. Predicate 510(k) number(s): k031797

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Device Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">LZI Methadone Metabolite(EDDP) EnzymeImmunoassay (k170416)</td><td colspan="1" rowspan="1">Predicate DeviceThe Lin-Zhi International,Inc. (LZI) MethadoneMetabolite (EDDP) EnzymeImmunoassay (k031797)</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">The LZI Methadone Metabolite(EDDP) Enzyme Immunoassayis intended for the qualitativeand semi-quantitativedetermination of methadonemetabolite (EDDP) in humanurine at cutoff valuesof 100 or 300 ng/mL. The assayis designed for professional usewith a number of automatedclinical chemistry analyzers.This assay provides a rapidscreening procedure fordetermining the presence ofmethadone metabolite in urine.The assay provides only apreliminary analytical result. Amore specific alternativechemical method must be usedin order to obtain a confirmedanalytical result. Gas or liquidchromatography/mass</td><td colspan="1" rowspan="1">The Lin-Zhi International, Inc.(LZI) Methadone Metabolite(EDDP) Enzyme Immunoassayis intended for the qualitativeand semi-quantitativedetermination of methadonemetabolite in human urine at acutoff value of 300 ng/mL. Theassay is designed forprofessional use with a numberof automated clinical chemistryanalyzers.This assay provides a rapidscreening procedure fordetermining the presence ofmethadone metabolite in urine.The assay provides only apreliminary analytical result. Amore specific alternativechemical method must be usedin order to obtain a confirmedanalytical result. Gas or liquid</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">spectrometry (GC/MS orLC/MS) is the preferredconfirmatory method. Clinicalconsideration and professionaljudgment should be exercisedwith any drug of abuse testresult, particularly when thepreliminary test result ispositive.</td><td colspan="1" rowspan="1">chromatography/massspectrometry (GC/MSor LC/MS) is the preferredconfirmatory method. Clinicalconsideration and professionaljudgment should be exercisedwith any drug of abuse testresult, particularly when thepreliminary test result ispositive.</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Methadone Metabolite (EDDP)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8°C until expiration date</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Device Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">LZI Methadone Metabolite(EDDP) Enzyme Immunoassay(k170416)</td><td colspan="1" rowspan="1">Predicate DeviceThe Lin-Zhi International,Inc. (LZI) MethadoneMetabolite (EDDP) EnzymeImmunoassay (k031797)</td></tr><tr><td colspan="1" rowspan="1">Cutoff</td><td colspan="1" rowspan="1">100 or 300 ng/ml</td><td colspan="1" rowspan="1">300 ng/mL</td></tr><tr><td colspan="3" rowspan="1">Calibrators Similarities and Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">LZI Methadone Metabolite(EDDP) Calibrators (k170416)</td><td colspan="1" rowspan="1">Predicate DeviceThe Lin-Zhi International,Inc. (LZI) Single Analyte(EDDP) Drug of AbuseCalibrators (k031797)</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">The LZI Methadone Metabolite(EDDP) (100 and 300)Calibrators are for use ascalibrators in the qualitative andsemiquantitativecalibration of the LZIMethadone Metabolite (EDDP)Enzyme Immunoassay at thecutoff values of100 ng/mL and300 ng/mL</td><td colspan="1" rowspan="1">The EDDP (methadonemetabolite) Drugs of AbuseCalibrators are intended for invitro diagnostic use for thecalibration of the methadonemetabolite enzymeimmunoassays to detectmethadone metabolite (EDDP)in human urine.</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

EP5-A, Evaluation of Precision Performance of Clinical Chemistry Devices, Vol. 19, No.2, February 1999.

# L. Test Principle:

The LZI Methadone Metabolite assay is a homogeneous enzyme immunoassay based on competition between EDDP in the sample and EDDP labeled with the enzyme glucose-6- phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. In the absence of EDDP in the sample, EDDP-labeled G6PDH conjugate is bound to antibody, and the G6PDH enzyme activity is inhibited. When free EDDP is present in the sample, it competes with EDDP-labeled G6PDH for binding to the antibody allowing for an amount of active G6PDH enzyme that is proportional to EDDP concentration. Active G6PDH enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at $3 4 0 \mathrm { n m }$ .

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision studies were carried out in qualitative and semi-quantitative mode. All methadone metabolite samples were tested in replicates of 2, two runs per day for 22 days on one Beckman Coulter AU480 automatic clinical analyzer for a total of 88 sample results. The samples were prepared by spiking drug into negative urine with the concentrations provided in the below tables. Each drug concentration was

confirmed by LC/MS. The results are summarized in the tables below, and were identical for each mode. Results are provided below.

Qualitatitive and Semi-Quantiatitive results at 100 ng/mL Cutoff:   

<table><tr><td rowspan=2 colspan=1>MethadoneMetabolite(EDDP)concetration(ng/mL)</td><td rowspan=2 colspan=1>LC/MSValue(ng/ml)</td><td rowspan=2 colspan=1>% ofcutoff</td><td rowspan=1 colspan=1>Within Run(N=22)</td><td rowspan=1 colspan=1>Total Precision(N=88)</td></tr><tr><td rowspan=1 colspan=1>ImmnoassayResult</td><td rowspan=1 colspan=1>ImmnoassayResult</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>57.2</td><td rowspan=1 colspan=1>-50 %</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>76.6</td><td rowspan=1 colspan=1>-25 %</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>103.5</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>11 Neg/11 Pos</td><td rowspan=1 colspan=1>40 Pos/48 Neg</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>165</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>175</td><td rowspan=1 colspan=1>179</td><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>192</td><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

Qualitatitive and Semi-Quantiatitive results at 300 ng/mL Cutoff:   

<table><tr><td rowspan=2 colspan=1>MethadoneMetabolite(EDDP)concetration(ng/mL)</td><td rowspan=2 colspan=1>LC/MSValue(ng/ml)</td><td rowspan=2 colspan=1>% ofcutoff</td><td rowspan=1 colspan=1>Within Run(N=22)</td><td rowspan=1 colspan=1>TotalPrecision</td></tr><tr><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>ImmnoassayResult</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>76.6</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>165</td><td rowspan=1 colspan=1>-50 %</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>233</td><td rowspan=1 colspan=1>-25 %</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>6 Neg/ 16 Pos</td><td rowspan=1 colspan=1>36 Neg/ 52 Pos</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>391</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>466</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>22Positive</td><td rowspan=1 colspan=1>88Positive</td></tr><tr><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>541</td><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>22Positive</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>657</td><td rowspan=1 colspan=1>+100</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

# $b$ . Linearity/assay reportable range:

A linearity study in the semi-quantitative mode was conducted by spiking a drug free urine pool to create a high concentration EDDP, and preparing serial dilutions with negative urine to achieve the EDDP concentrations provided in the tables below. Each level was tested in triplicate on the Beckman Coulter AU480 automated clinical chemistry analyzer. The concentrations were confirmed by LC/MS. The results of the linearity/recovery study are summarized below:

<table><tr><td rowspan=1 colspan=3>Linearity: 100 ng/mL Cutoff</td></tr><tr><td rowspan=1 colspan=1>ExpectedConcentration(ng/mL)</td><td rowspan=1 colspan=1>ObservedConcetration(ng/mL)</td><td rowspan=1 colspan=1>Recovery (%)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-3.1</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>51.7</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>49.0</td><td rowspan=1 colspan=1>97.7</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.8</td><td rowspan=1 colspan=1>98.8</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>153.7</td><td rowspan=1 colspan=1>102.5</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>203.0</td><td rowspan=1 colspan=1>101.5</td></tr><tr><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>245.8</td><td rowspan=1 colspan=1>98.3</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>312.7</td><td rowspan=1 colspan=1>104.2</td></tr><tr><td rowspan=1 colspan=1>350</td><td rowspan=1 colspan=1>369.1</td><td rowspan=1 colspan=1>105.5</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>412.9</td><td rowspan=1 colspan=1>103.2</td></tr><tr><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>443.0</td><td rowspan=1 colspan=1>98.4</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>478.2</td><td rowspan=1 colspan=1>95.6</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Linearity: 300 ng/mL Cutoff</td></tr><tr><td rowspan=1 colspan=1>ExpectedConcentration(ng/mL)</td><td rowspan=1 colspan=1>ObservedConcetration(ng/mL)</td><td rowspan=1 colspan=1>Recovery (%)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-6.4</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>29.0</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>83.1</td><td rowspan=1 colspan=1>83.1</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>196.2</td><td rowspan=1 colspan=1>98.1</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>295.9</td><td rowspan=1 colspan=1>96.6</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>422.5</td><td rowspan=1 colspan=1>105.6</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>519.0</td><td rowspan=1 colspan=1>103.8</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>595.3</td><td rowspan=1 colspan=1>99.2</td></tr><tr><td rowspan=1 colspan=1>700</td><td rowspan=1 colspan=1>709.4</td><td rowspan=1 colspan=1>101.3</td></tr><tr><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>807.1</td><td rowspan=1 colspan=1>100.9</td></tr><tr><td rowspan=1 colspan=1>900</td><td rowspan=1 colspan=1>878.4</td><td rowspan=1 colspan=1>97.6</td></tr><tr><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>940.9</td><td rowspan=1 colspan=1>94.1</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability and value assigment

Calibrators are prepared from a standard solution of EDDP purchased from a commercial vendor. This standard solution is diluted with drug-free synthetic urine matrix. The concentrations of the prepared solutions are confirmed by LC/MS.

# Stability

Accelerated and real-time stability studies were conducted and the stability protocols and acceptance criteria were reviewed and found to be acceptable. The study results support the stability claim of eighteen (18) months when the LZI Methadone Metabolites EDDP Calibrators are stored at 2 to $8 \ : ^ { \circ } \mathrm { C }$ .

d. Detection limit: Not applicable.

e. Analytical specificity:

Compounds sharing structural similarity with EDDP were tested for cross-reactivity with the candidate device. The structurally related compounds that exhibited crossreactivity with the candidate device were titrated to determine the lowest concentration that generated a positive result. The concentration $( \mathrm { n g / m L } )$ of crossreactant that gives a response equivalent to the cutoff, and the calculated percent cross-reactivity are presented in the table below.

Methadone Metabolite and Structurally Related Compounds for $1 0 0 ~ \mathrm { { n g / m L } }$ Cutoff:   

<table><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentration(ng/mL)</td><td rowspan=1 colspan=1>CrossReactivity(%)</td></tr><tr><td rowspan=1 colspan=1>EDDP</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100 %</td></tr><tr><td rowspan=1 colspan=1>EMDP</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>Methadone</td><td rowspan=1 colspan=1>300,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>LAAM HC1</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>(±)-α-Methadol</td><td rowspan=1 colspan=1>300,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>(-)-Isomethadone HCl</td><td rowspan=1 colspan=1>60,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>(-)-o-NbracetyImethadol(Nor-LAAM) HCl</td><td rowspan=1 colspan=1>300,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr></table>

Methadone Metabolite and Structurally Related Compounds for $3 0 0 ~ \mathrm { { n g / m L } }$ Cutoff:   

<table><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concntration(ng/mL)</td><td rowspan=1 colspan=1>CrossReactivity(%)</td></tr><tr><td rowspan=1 colspan=1>EDDP</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>100 %</td></tr><tr><td rowspan=1 colspan=1>EMDP</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>Methadone</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>LAAM HC1</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>(±)-α-Methadol</td><td rowspan=1 colspan=1>300,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>(-)-Isomethadone HCl</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr><tr><td rowspan=1 colspan=1>(-)-αt-Nbracetylmethadol(Nor-LAAM) HCI</td><td rowspan=1 colspan=1>300,000</td><td rowspan=1 colspan=1>&lt;0.1 %</td></tr></table>

Potential interfering substances found in human urine of physiological or pathological conditions were added to drug-free urine. Samples were tested with Methadone Metabolite (EDDP) concentrations of $0 \mathrm { n g / m L }$ , $- 2 5 \%$ of cut off and $+ 2 5 \%$ of cut off. No interference was observed at the concentrations tested. Results are summarized below.

Structurally Unrelated Pharmacological Compounds for $1 0 0 ~ \mathrm { { n g / m L } }$ Cutoff:   

<table><tr><td colspan="1" rowspan="1">Interfering Substances</td><td colspan="1" rowspan="1">Maximun concetrationtested without interference(ng/mL)</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">6-Acetylmorphine</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Alimemazine</td><td colspan="1" rowspan="1">1,000</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Amlodipine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">d-Amphetamine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Atorvastatin</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine</td><td colspan="1" rowspan="1">15,000</td></tr><tr><td colspan="1" rowspan="1">Bupropion</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Cetirizine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Chlorpheniramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">50,000</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Cyamemazine</td><td colspan="1" rowspan="1">12,000</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Doxylamine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Duloxetin</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Fentanyl</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Fluoxetine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Fluphenazine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Gabapentin</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Hemoblogin</td><td colspan="1" rowspan="1">300,000</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">buprofen</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Levomepromazine</td><td colspan="1" rowspan="1">40,000</td></tr><tr><td colspan="1" rowspan="1">Lisinopril</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Losartan</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Loratidine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">MDA (3,4-methylene-dioxyamphetamine)</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">MDEA</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">MDMA (3,4-methylene-dioxymethylamphetamine)</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Metformin</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Methylphenidate</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Metoprolol</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">d-Methamphetamine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Methapyrilene</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Methaqualone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Metronidazole</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Nortriptyline</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Omeprazole</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Phencyclidine</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Promethazine</td><td colspan="1" rowspan="1">5,000</td></tr><tr><td colspan="1" rowspan="1">(1S,2S)-(+)Pseudoephedrine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Quetiapine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Ranitidine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Salbutamol (Albuterol)</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Sertraline</td><td colspan="1" rowspan="1">5,000</td></tr><tr><td colspan="1" rowspan="1">THC-COOH(11-Nor-Delta-9-THC9carboxylic acid)</td><td colspan="1" rowspan="1">1,000</td></tr><tr><td colspan="1" rowspan="1">Thioridazine</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">L-Thyroxine</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Tramadol</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Zolpidem</td><td colspan="1" rowspan="1">10,000</td></tr></table>

Structurally Unrelated Pharmacological Compounds for $3 0 0 ~ \mathrm { { n g / m L } }$ Cutoff:   

<table><tr><td colspan="1" rowspan="1">Interfering Substances</td><td colspan="1" rowspan="1">Maximun concetrationtested without interference(ng/mL)</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">6-Acetylmorphine</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Alimemazine</td><td colspan="1" rowspan="1">4,000</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Amlodipine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">d-Amphetamine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Atorvastatin</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine</td><td colspan="1" rowspan="1">15,000</td></tr><tr><td colspan="1" rowspan="1">Bupropion</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Cetirizine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Chlorpheniramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Cyamemazine</td><td colspan="1" rowspan="1">25,000</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Doxylamine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Duloxetin</td><td colspan="1" rowspan="1">60,000</td></tr><tr><td colspan="1" rowspan="1">Fentanyl</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Fluoxetine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Fluphenazine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Gabapentin</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">300,000</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Levomepromazine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Lisinopril</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Losartan</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Loratidine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">MDA (3,4-methylene-dioxyamphetamine)</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">MDEA</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">MDMA (3,4-methylene-dioxymethylamphetamine)</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Metformin</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Methylphenidate</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Metoprolol</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">d-Methamphetamine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Methapyrilene</td><td colspan="1" rowspan="1">40,000</td></tr><tr><td colspan="1" rowspan="1">Methaqualone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Metronidazole</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Nortriptyline</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Omeprazole</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Phencyclidine</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Promethazine</td><td colspan="1" rowspan="1">15,000</td></tr><tr><td colspan="1" rowspan="1">(1S,2S)-(+)Pseudoephedrine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Quetiapine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Ranitidine</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Salbutamol (Albuterol)</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Sertraline</td><td colspan="1" rowspan="1">15,000</td></tr><tr><td colspan="1" rowspan="1">THC-COOH(11-Nor-Delta-9-THC9carboxylic acid)</td><td colspan="1" rowspan="1">1,000</td></tr><tr><td colspan="1" rowspan="1">Thioridazine</td><td colspan="1" rowspan="1">90,000</td></tr><tr><td colspan="1" rowspan="1">L-Thyroxine</td><td colspan="1" rowspan="1">10,000</td></tr><tr><td colspan="1" rowspan="1">Tramadol</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">100,000</td></tr><tr><td colspan="1" rowspan="1">Zolpidem</td><td colspan="1" rowspan="1">10,000</td></tr></table>

# Effect of Urine Specific Gravity

To investigate the effect of urine specific gravity, urine samples with 1.004 to 1.025 specific gravity were spiked with EDDP at $- 2 5 \%$ of cut off and $+ 2 5 \%$ of cut-off. Samples were then evaluated against the assay’s calibration curve in both qualitative and semi-quantitative modes. No interference was observed.

# Effect of pH

Urine samples with pH 3 to11 were spiked with EDDP at $- 2 5 \%$ of cut off and $+ 2 5 \%$ of cut-off. Samples were then evaluated against the assay’s calibration curve in both qualitative and semi-quantitative modes. No interference was observed.

f. Assay cut-off:

Characterization of how the device performs analytically around the claimed cutoff concentration is described in the precision section, M.1.a. above.

2. Comparison studies:

# a. Method comparison with predicate device:

Method comparison studies for the LZI Methadone Metabolite Enzyme Immunoassay were conducted on the Beckman Coulter AU480 automated clinical analyzer. All samples were confirmed with LC/MS for both methadone and methadone metabolite concentrations. For the $1 0 0 ~ \mathrm { { n g / m L } }$ cutoff, a total total of eighty-seven (87) unaltered clinical samples were tested. The results were identical when determined in qualitative or semi-quantitative mode, and are summarized in the following table:

<table><tr><td rowspan=2 colspan=1>CandidateDeviceResult</td><td rowspan=1 colspan=5>EDDP Concentrationby LC/MS (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Drug-free</td><td rowspan=1 colspan=1>LowNegative(&lt;50%thecutoffconc)</td><td rowspan=1 colspan=1>NearCutoffNegative(Between&lt;50%below upto thecutoffconc)</td><td rowspan=1 colspan=1>NearCutoffPositive(Betweenthecutoffand50%abovecutoffconc)</td><td rowspan=1 colspan=1>HighPositive(&gt;50%abovethecutoffconc)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>0</td></tr></table>

\*Samples have discordant negative immunoassay results when compared to LC/MS, as summarized in the following table:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Candidate Device Result</td><td rowspan=2 colspan=1>EDDPLC/MS result(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Semi-quantitative</td></tr><tr><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>103</td></tr><tr><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>126</td></tr></table>

For the $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff, a total total of eighty-seven (84) unaltered clinical samples were tested. The results were identical when determined in qualitative or semiquantitative mode, and are summarized in the following table:

<table><tr><td colspan="1" rowspan="3">CandidateDeviceResult</td><td colspan="5" rowspan="1">EDDP Concentrationby LC/MS (ng/mL)</td></tr><tr><td colspan="1" rowspan="2">Drug-free</td><td colspan="1" rowspan="2">LowNegative(&lt;50%thecutoffconc)</td><td colspan="1" rowspan="1">Near</td><td colspan="1" rowspan="1">Near</td><td colspan="1" rowspan="2">HighPositive(&gt;50%abovethecutoffconc)</td></tr><tr><td colspan="1" rowspan="1">CutoffNegative(Between&lt;50%below upto thecutoffconc)</td><td colspan="1" rowspan="1">CutoffPositive(Betweenthecutoffand50%above</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">cutoffconc)</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">38</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr></table>

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: No applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.